10/706,659 Wcook 1/8/06 Search.

d his

(FILE 'HOME' ENTERED AT 15:54:04 ON 08 JAN 2006)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 15:54:22 ON 08 JAN 2006

L1 17 S IK17?

L2 8 DUPLICATE REMOVE L1 (9 DUPLICATES REMOVED)

=>

d his

(FILE 'HOME' ENTERED AT 15:54:04 ON 08 JAN 2006)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 15:54:22 ON 08 JAN 2006

L1 17 S IK17?

L2 8 DUPLICATE REMOVE L1 (9 DUPLICATES REMOVED)

=>

```
ANSWER 5 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
     DUPLICATE 3
AN
     1997:112650 BIOSIS
DN
     PREV199799411853
TI
     DELTA-IK17 antigen: A possible early marker of cancer
     development.
     Perez, S. [Reprint author]; Sotiriadou, R.; Missitzis, G.; Trangas, T.;
ΑU
     Giannoulis, N.; Mavroudeas, D.; Apostolikas, N.; Kokkinopoulos, D.
     Dep. Immunol., Hellenic Anticancer Inst., 171 Alexandras Ave., 11522
CS
     Athens, Greece
     International Journal of Biological Markers, (1996) Vol. 11, No. 4, pp.
SO
     190-197.
     CODEN: IBMAEP. ISSN: 0393-6155.
DT
     Article
LA
     English
     Entered STN: 10 Mar 1997
ED
     Last Updated on STN: 10 Mar 1997
     DELTA-IK17 is a 44 kD molecule located on the surface of T, B
AB
     and NK cells in normal peripheral blood mononuclear cells (PBMC) (1).
     portion of PBMC expressing DELTA-IK17 was determined in 52
     patients with benign breast diseases, 182 patients with breast
     malignancies and 132 healthy individuals. The percentage of DELTA-
     IK17-positive cells was significantly lower in the early stages
     (I-IIA) of malignancy compared to that of healthy donors. However, the
     percentage of PBMC expressing DELTA-IK17 tended to increase as
     the stage of the disease advanced. DELTA-IK17 seems to be the
     only antigen among the other cellular markers tested (CD2, CD4, CD8,
     HLA-DR) with a statistically significant correlation between a low
     percentage of positive cells and the early stages of malignancy and
     between a high expression and advanced disease. Its potential use as a
     tumor marker in breast cancer is discussed here.
     Biochemistry studies - Proteins, peptides and amino acids
                                                                  10064
CC
     Pathology - Diagnostic
                              12504
     Neoplasms - Diagnostic methods
                                      24001
     Major Concepts
IT
        Oncology (Human Medicine, Medical Sciences)
IT
     Miscellaneous Descriptors
        BIOCHEMISTRY AND BIOPHYSICS; CANCER; CANCER DEVELOPMENT EARLY MARKER;
        DELTA-IK17 ANTIGEN; NEOPLASTIC DISEASE; ONCOLOGY; PATIENT
ORGN Classifier
       Hominidae
                    86215
     Super Taxa
        Primates; Mammalia; Vertebrata; Chordata; Animalia
     Organism Name
        human
     Taxa Notes
```

Animals, Chordates, Humans, Mammals, Primates, Vertebrates

```
ANSWER 5 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
     DUPLICATE 3
AN
     1997:112650 BIOSIS
DN
     PREV199799411853
     DELTA-IK17 antigen: A possible early marker of cancer
ΤI
     development.
     Perez, S. [Reprint author]; Sotiriadou, R.; Missitzis, G.; Trangas, T.;
ΑU
     Giannoulis, N.; Mavroudeas, D.; Apostolikas, N.; Kokkinopoulos, D.
CS
     Dep. Immunol., Hellenic Anticancer Inst., 171 Alexandras Ave., 11522
     Athens, Greece
     International Journal of Biological Markers, (1996) Vol. 11, No. 4, pp.
SO
     190-197.
     CODEN: IBMAEP. ISSN: 0393-6155.
DT
     Article
LA
     English
     Entered STN: 10 Mar 1997
ED
     Last Updated on STN: 10 Mar 1997
AB
     DELTA-IK17 is a 44 kD molecule located on the surface of T, B
     and NK cells in normal peripheral blood mononuclear cells (PBMC) (1).
     portion of PBMC expressing DELTA-IK17 was determined in 52
     patients with benign breast diseases, 182 patients with breast
     malignancies and 132 healthy individuals. The percentage of DELTA-
     IK17-positive cells was significantly lower in the early stages
     (I-IIA) of malignancy compared to that of healthy donors. However, the
     percentage of PBMC expressing DELTA-IK17 tended to increase as
     the stage of the disease advanced. DELTA-IK17 seems to be the
     only antigen among the other cellular markers tested (CD2, CD4, CD8,
     HLA-DR) with a statistically significant correlation between a low
     percentage of positive cells and the early stages of malignancy and
     between a high expression and advanced disease. Its potential use as a
     tumor marker in breast cancer is discussed here.
     Biochemistry studies - Proteins, peptides and amino acids
                                                                 10064
     Pathology - Diagnostic
                              12504
     Neoplasms - Diagnostic methods
                                      24001
IT
     Major Concepts
        Oncology (Human Medicine, Medical Sciences)
IT
     Miscellaneous Descriptors
        BIOCHEMISTRY AND BIOPHYSICS; CANCER; CANCER DEVELOPMENT EARLY MARKER;
       DELTA-IK17 ANTIGEN; NEOPLASTIC DISEASE; ONCOLOGY; PATIENT
ORGN Classifier
       Hominidae
                    86215
     Super Taxa
       Primates; Mammalia; Vertebrata; Chordata; Animalia
     Organism Name
       human
     Taxa Notes
       Animals, Chordates, Humans, Mammals, Primates, Vertebrates
```